Halozyme views its drug delivery technology for biologic medicines as complementary to Evotec’s biologic drug manufacturing capabilities. But according to Halozyme, Evotec was unwilling to engage in any merger discussions.
The post Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy appeared first on MedCity News.
